Pain Management Drugs Market Size, Share, and Trends 2024 to 2033

Pain Management Drugs Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, Hospital Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 2494
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pain Management Drugs Market 

5.1. COVID-19 Landscape: Pain Management Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pain Management Drugs Market, By Drug Class

8.1. Pain Management Drugs Market, by Drug Class, 2022-2032

8.1.1 NSAIDs

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Opioids

8.1.2.1. Market Revenue and Forecast (2022-2032)

8.1.3. Anesthetics

8.1.3.1. Market Revenue and Forecast (2022-2032)

8.1.4. Antidepressants

8.1.4.1. Market Revenue and Forecast (2022-2032)

8.1.5. Anticonvulsants

8.1.5.1. Market Revenue and Forecast (2022-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2022-2032)

Chapter 9. Global Pain Management Drugs Market, By Indication

9.1. Pain Management Drugs Market, by Indication, 2022-2032

9.1.1. Arthritic Pain

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Neuropathic Pain

9.1.2.1. Market Revenue and Forecast (2022-2032)

9.1.3. Chronic Back Pain

9.1.3.1. Market Revenue and Forecast (2022-2032)

9.1.4. Post-Operative Pain

9.1.4.1. Market Revenue and Forecast (2022-2032)

9.1.5. Cancer Pain

9.1.5.1. Market Revenue and Forecast (2022-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2022-2032)

Chapter 10. Global Pain Management Drugs Market, By Distribution Channel 

10.1. Pain Management Drugs Market, by Distribution Channel, 2022-2032

10.1.1. Online Pharmacy

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Retail Pharmacy

10.1.2.1. Market Revenue and Forecast (2022-2032)

10.1.3. Hospital Pharmacy

10.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 11. Global Pain Management Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.1.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.2.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.3.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2022-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2022-2032)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Pfizer

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Abbott

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Mallinckrodt Pharmaceuticals

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Endo International

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. GlaxoSmithKline

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Depomed

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Merck

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Novartis

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client